Ganzetti Giulia, Campanati Anna, Molinelli E, Offidani A
Dermatologic Clinic, Polytechnic University of Marche Region, Ancona, Via Conca, 71, 60126 Ancona, Italy.
Curr Drug Saf. 2016;11(1):12-21. doi: 10.2174/1574886310666151014121732.
Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis. Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa. Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series. The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
生物治疗已经改变了许多皮肤病和非皮肤病治疗的武器库，文献数据广泛聚焦于肿瘤坏死因子-α抑制剂在银屑病治疗中的疗效和安全性。尽管发病机制尚未完全阐明，但炎症似乎是统一多种皮肤病（如特应性皮炎、斑秃和化脓性汗腺炎）免疫发病机制的主要因素。实际上，关于生物制剂在皮肤免疫介导的炎症性疾病中的非标签使用的数据很少，且仅限于个案和病例系列。本综述旨在证明肿瘤坏死因子-α抑制剂在皮肤科的主要非标签使用情况。
